PMHNP Confidence
Saying No to Controlled Substances: A New PMHNP Confidence Script
A new PMHNP confidence script for declining inappropriate controlled substance requests — with exact language, rationale, and de-escalation frameworks.
Tagged
Prescribing
Real talk about psychopharmacology, clinical confidence, and building a practice you love — from Lindsay and the Fellowship faculty.
More Articles
Clinical Practice
Managing Psychiatric Medication Side Effects: A PMHNP Clinical Decision Guide
Side effect management is where PMHNPs earn patient trust and medication adherence. This clinical decision guide covers evidence-based strategies for the...
Clinical Practice
Psychiatric Medication Interactions Every PMHNP Should Have Memorized
Dangerous psychiatric medication interactions cause thousands of preventable adverse events annually. This reference guide covers the critical...
Clinical Practice
Ketamine and Esketamine in Psychiatric Practice: What PMHNPs Need to Know in 2026
Ketamine and esketamine are reshaping treatment-resistant depression care, with expanded indications and new delivery models emerging in 2026.
Clinical Practice
Buprenorphine Prescribing for PMHNPs: What Changed After the X-Waiver Elimination
With the X-waiver eliminated, all DEA-licensed PMHNPs can now prescribe buprenorphine for opioid use disorder without special certification.
Career & Business
DEA Telehealth Prescribing Rules for 2026: What PMHNPs Running a Practice Need to Know
The DEA extended telehealth prescribing flexibilities for controlled substances through December 2026. Here's what PMHNPs building telehealth practices need to know before permanent rules arrive.
Clinical Practice
FDA ADHD Stimulant Label Change: Weight Loss Risk PMHNPs Must Know
The FDA now requires weight loss warnings on all extended-release ADHD stimulants for patients under 6. Here's what PMHNPs need to know about monitoring, documentation, and the 10% weight percentile threshold.
Clinical Practice
Bysanti (Milsaperidone) FDA Approval: What PMHNPs Need to Know
The FDA just approved Bysanti (milsaperidone) for bipolar I and schizophrenia. Here's what PMHNPs need to know about dosing, monitoring, and where it fits in your prescribing toolkit.